Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000727 · ClinicalTrials.gov registry record · Phase 3
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,026
- Enrollment target
NCT01000727: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT01000727 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 13,026 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1589% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01000727, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,026 participants
- Enrollment target
Study Summary
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).
Primary Outcome
Coronary heart disease (CHD) death=occurrence of a fatal myocardial infarction (MI), death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/
Interventions
- DRUG Placebo
- OTHER Standard Therapy
- DRUG Darapladib 160 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,026 participants |
| Start Date | 2009-12-01 |
| Est. Completion | 2014-04-24 |
| Phase | Phase 3 |
What the finished NCT01000727 record still lists
NCT01000727 is an interventional study that assigns participants to a tested intervention. Its 13,026 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1589% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01000727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01000727 about?
NCT01000727 is a clinical study titled "The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial". This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 3...
What is the current status of trial NCT01000727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,026 participants. The study started on 2009-12-01. Estimated completion is 2014-04-24.
What interventions are being tested in trial NCT01000727?
The interventions under investigation include: Placebo (DRUG), Standard Therapy (OTHER), Darapladib 160 mg (DRUG).
Who is sponsoring clinical trial NCT01000727?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01000727's enrollment target sits among peer trials
13,026 17th of 2000 higher than 1,984 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07177352 · 13,000 participants · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI